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Abstract: Biosimilars are a growing drug class designed 
to be used interchangeably with biologics. Biologics are 
created in living cells and are typically large, complex 
proteins that may have a variety of uses. Within the field of 
gastroenterology alone, biologics are used to treat 
inflammatory bowel diseases, cancers, and endocrine 
disorders. A biosimilar is a drug that is highly similar, but not 
necessarily identical, to a biologic drug (i.e., the reference 
drug) and shows no clinically significant differences in 
safety, purity, or potency. Biosimilar development does not 
establish safety and efficacy, but rather shows bio similarity 
to the reference drug. Unlike generic drugs, biosimilars are 
not an exact copy of their reference drug because of 
differences in the manufacturing. 
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I.  INTRODUCTION 
Biologics are derived from the natural resources such as 
human, animal, or microorganism and manufactured by 
various biotechnology methods such as recombinant 
deoxyribonucleic acid technology, controlled gene 
expression, and antibody technology. Biologics have 
benefitted the patients with rheumatologic diseases, 
inflammatory bowel disease, malignant conditions, 
dermatological conditions, and other connective tissue 
disorders by halting the disease progression, alleviating the 
symptoms, and improving the quality of life.[1, 2] Biologics 
are one of the top selling drugs worldwide as well as in the 
United States but the major drawback of this drug has been 
its exorbitant cost, which makes it unaffordable and 
inaccessible to many patients, especially in developing 
countries where a large number of people are poor and the 
concept of health insurance is at its nascent stage.[3,4] 
biologic product, which is very similar to Food and Drug 
Administration (FDA)-approved biological product known as 
reference product and has no clinically meaningful 
differences in term of safety and effectiveness from the 
reference product.[5] Health-care experts and physicians are 
optimistic that use of biosimilars may reduce the cost of 
biologics and eventually lead to better patients’ access to 
these lifesaving drugs[6]. 
 
II. NAMING OF BIOSIMILAR 
To assign a proper name to a drug, a core name or generic 
is designated by the United States Adopted Names Council 
for originator biologic drugs. This core name carries over if 
the biologic drug is a related biologic drug, a biosimilar, or 
an interchangeable drug. Four meaningless lowercase letters 
are then added after a hyphen to the end of the core name [8]. 
III.  IMPACT OF BIOSIMILAR 
 Even with the inherent constraints of biosimilar 
substitution, introduction of biosimilars in the Hong Kong 
market is expected to bring the impact on various aspects, 
including patient, public health system, private healthcare. 
Pharmacodynomic Value of Biosimilars: 
A fundamental aim in developing biosimilars is to 
improve patient outcomes by offering access to biologics 
with improved affordability. Bearing in mind that the primary 
purpose of biosimilar clinical study programs is to confirm 
comparable efficacy and safety in a sensitive patient 
population, the availability of such data has nevertheless 
enabled the development of cost models to ascertain the 
feasibility of potential cost savings with biosimilars 
compared with their reference products. 
IV. BIOSIMILAR IS BIOLOGICAL MEDICINE 
Biological medicines offer treatment options for patients 
with chronic and often disabling conditions such as diabetes, 
autoimmune disease and cancers. Biological 
medicines contain active substances from a biological 
source, such as living cells or organisms (human, animals and 
microorganisms such as bacteria or yeast) and are often 
produced by cutting-edge technology. Most biological 
medicines in current clinical use contain active 
substances made of proteins. These can differ in size and 
structural complexity, from simple proteins like insulin or 
growth hormone to more complex ones such as coagulation 
factors or monoclonal antibodies. 
The EU approved the first biosimilar in 2006. 
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A biosimilar is not regarded as a generic of a biological 
medicine. This is mostly because the natural variability and 
more complex manufacturing of biological medicines do not 
allow an exact replication of the molecular micro-
heterogeneity. The EU has pioneered the regulation 
of biosimilar medicines by establishing a solid 
framework for their approval and by shaping biosimilar 
development globally. The evidence acquired over ten years 
of clinical experience shows that biosimilars approved 
through EMA can be used as safely and effectively in all their 
approved indications as other biological medicines[10]. 
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